What the FDA labels say about taking them together
Atazanavir and progesterone
Atazanavir's FDA label of August 6, 2025 names progesterone in its drug interactions section; the progesterone labels PlainMeds reads (3) do not name atazanavir. The atazanavir label: “Potential safety risks include substantial increases in progesterone exposure.”
Check it at the source: the atazanavir FDA label on DailyMed (effective August 6, 2025, Aurobindo Pharma Limited); the progesterone FDA label on DailyMed (effective July 23, 2026, Acertis Pharmaceuticals, LLC).
What does the atazanavir label say about progesterone?
Atazanavir label, drug interactionsPotential safety risks include substantial increases in progesterone exposure.
Source: FDA drug label (Atazanavir Sulfate), Aurobindo Pharma Limited, effective August 6, 2025 (SPL set 7fbea274-d6b5-4faa-bbf0-05fefab42114), via openFDA; the full label on DailyMed
What does the progesterone label say about atazanavir?
Progesterone's label (effective July 23, 2026) and its 2 other brand-application labels do not name atazanavir in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Prometrium), Acertis Pharmaceuticals, LLC, effective July 23, 2026 (SPL set 1cf237ff-c4f8-4faa-a7aa-77599c856889), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atazanavir | Progesterone | |
|---|---|---|
| Labeled for | HIV | n/a |
| Boxed warning | No | No |
| Pharmacy cost (NADAC) | $2.23 per capsule 300 mg capsule | $0.229 per capsule 100 mg capsule |
| Shortage now | No current entry | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once